A Phase Ib Study to Evaluate the Efficacy and Safety of HRS-2129 in Patients With Knee Osteoarthritis

This Phase 1b study is testing a new investigational drug called HRS-2129 at different doses to see how well it relieves moderate to severe knee pain caused by osteoarthritis, and to assess its safety and how the body processes it. Knee osteoarthritis is a degenerative joint condition causing cartilage breakdown, pain, and reduced mobility. Adults with knee osteoarthritis whose pain scores 4 or more out of 10, who are willing to stop other pain medications (except acetaminophen) during the study, and who do not have a recent history of knee surgery, severe health conditions, or malignancy are eligible. Participation involves receiving HRS-2129 injections or infusions at different dose levels, with clinic visits for pain assessments, blood samples for drug level monitoring, and safety evaluations. This summary was prepared with AI assistance to help patients understand the study in plain language.